Efficacy and Safety of Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis of Interventional Evidence
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Traditional diabetes self-monitoring of blood glucose (SMBG) involves inconvenient finger pricks. Continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems offer CGM, enhancing type 2 diabetes (T2D) management with convenient, comprehensive data. PURPOSE: To assess the benefits and potential harms of CGM and isCGM compared with usual care or SMBG in individuals with T2D. DATA SOURCES: We conducted a comprehensive search of MEDLINE, Embase, the Cochrane Library, Web of Science, and bibliographies up to August 2023. STUDY SELECTION: We analyzed studies meeting these criteria: randomized controlled trials (RCT) with comparison of at least two interventions for ≥8 weeks in T2D patients, including CGM in real-time/retrospective mode, short-/long-term CGM, isCGM, and SMBG, reporting glycemic and relevant data. DATA EXTRACTION: We used a standardized data collection form, extracting details including author, year, study design, baseline characteristics, intervention, and outcomes. DATA SYNTHESIS: We included 26 RCTs (17 CGM and 9 isCGM) involving 2,783 patients with T2D (CGM 632 vs. usual care/SMBG 514 and isCGM 871 vs. usual care/SMBG 766). CGM reduced HbA1c (mean difference -0.19% [95% CI -0.34, -0.04]) and glycemic medication effect score (-0.67 [-1.20 to -0.13]), reduced user satisfaction (-0.54 [-0.98, -0.11]), and increased the risk of adverse events (relative risk [RR] 1.22 [95% CI 1.01, 1.47]). isCGM reduced HbA1c by -0.31% (-0.46, -0.17), increased user satisfaction (0.44 [0.29, 0.59]), improved CGM metrics, and increased the risk of adverse events (RR 1.30 [0.05, 1.62]). Neither CGM nor isCGM had a significant impact on body composition, blood pressure, or lipid levels. LIMITATIONS: Limitations include small samples, single-study outcomes, population variations, and uncertainty for younger adults. Additionally, inclusion of <10 studies for most end points restricted comprehensive analysis, and technological advancements over time need to be considered. CONCLUSIONS: Both CGM and isCGM demonstrated a reduction in HbA1c levels in individuals with T2D, and unlike CGM, isCGM use was associated with improved user satisfaction. The impact of these devices on body composition, blood pressure, and lipid levels remains unclear, while both CGM and isCGM use were associated with increased risk of adverse events.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
1 retracted
Tildesley, H. D., Wright, A. M., Chan, J. H. M., Mazanderani, A. B., Ross, S. A., Tildesley, H. G., Lee, A. M., Tang, T. S., & White, A. S. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.05.006 · Cited by 20
RetractedBias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Rayyan-a web and mobile app for systematic reviews.
Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0384-4 · Cited by 26,092
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
Beck, R. W., Riddlesworth, T. D., Ruedy, K., Ahmann, A., Haller, S., Kruger, D., McGill, J. B., Polonsky, W., Price, D., Aronoff, S., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2855 · Cited by 635
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017) · Diabetes Therapy · doi:10.1007/s13300-016-0223-6 · Cited by 623
Self-citation
Cited by
Items 101–120 of 120
Definitions and Introduction to Medical Innovation
Le, P. T., & Dickson, C. A. (2026) · Springer eBooks · doi:10.1007/978-3-032-19116-8_2
Hayek, A. A., Zahrani, W. M. A., Alotaibi, H. F., & Dawish, M. A. A. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261447256 · Cited by 1
Kotowicz, M., Koczkodaj, M., Szajewski, P., Zielińska, M., Bieniak-Pentchev, M., Zagórska, A., & Ciećwierz, J. (2026) · Annales Academiae Medicae Silesiensis · doi:10.18794/aams/214253 · Cited by 1
“Furthermore, CGM has been shown to support improved self-management and to be correlated with reductions in HbA1c levels among individuals with type 2 diabetes [15,16,17,18].”
Joung, K.-I., Hwang, J. W., Seo, S. Y., Back, K. H., Jeon, Y. G., & Kim, K. J. (2026) · PLoS ONE · doi:10.1371/journal.pone.0350025
Alabdulkarim, H. A., Al-Shraim, M., Motahari-Nezhad, H., Fgaier, M., Péntek, M., Gulàcsi, L., Aldahash, R., & Zrubka, Z. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261445111 · Cited by 1
Alimbayeva, Z. N., Alimbayev, C. A., Ozhikenov, K., Ozhikenova, A. K., Shylmyrza, U., & Khaidarova, K. (2026) · Applied Sciences · doi:10.3390/app16115359
Park-Chong, H., Benrimon, M., & Smaldone, A. M. (2026) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106261451194
Zhang, M., LU, Y., Ling, H., Hu, W., Zheng, X., Huang, M., Zhao, M., Wang, X., Zhang, G., Zhang, Y., et al. (2026) · Journal of Diabetes Science and Technology · doi:10.1177/19322968261445103
Balaji, R. S., Vinith, V., Kannan, R., Ramadurai, M., & Murugan, P. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100724 · Cited by 1
Zhang, X., Bai, N., Mao, C.-P., & Liu, C.-Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1863226 · Cited by 2
“With continuous glucose monitoring (CGM) now being used more widely in clinical practice, it is possible to quantify GV using a range of metrics, thereby providing a more detailed view of glycemic control than HbA1c alone (9 – 11).”
Bazan, A., Plichta, O., Radzinska, N., & Kalinowska, K. (2026) · Cureus · doi:10.7759/cureus.112200
Thomsen, T. L., Petersen, M. C., Abrahamsen, L., Nielsen, T. D., Schousboe, K., Möller, S., & Schultz, H. (2026) · Diabetic Medicine · doi:10.1111/dme.70422
Challenges Implementing Remote Patient Monitoring for Hypertension—Reply
Ünlü, O., & Fisher, N. D. L. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.2101
Model-Driven Discovery of Highly Sensitive Nanocolumnar NiO Electrochemical Glucose Sensors
Bigdeli, M. M., Bruce, J., Jemere, A. B., Harris, K. D., & Stroberg, W. (2026) · ACS Engineering Au · doi:10.1021/acsengineeringau.6c00026 · Cited by 1
Hannah, K. L., Nemlekar, P. M., & Norman, G. J. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.26112
Continuous Glucose Monitoring in Type 2 Diabetes and Beyond: A Review
Dower, J. A., Johansson, M., CAMP, A. W., Montori, V. M., & Lipska, K. J. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2026.2772 · Cited by 2
Rehman, K., & Akash, M. S. H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45911-5.00015-5
Bergenstal, R. M., Davidson, M. B., Ahn, D. T., Aleppo, G., Martens, T. W., Miller, E. M., Duke, D. L., Case, M. G., Ilag, L. L., JOHNSON, J., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261485755
Tyagi, S., Sng, K. C. M., Ng, D. W. L., Teo, V. H. Y., Thio, S. M., Beh, C. Y., Cheah, M. H., Toh, N. M. B. M. J. S., He, J. C. E., & Koh, G. C. (2026) · doi:10.2196/preprints.111754
Gómez, P. R. D. V., Díaz, Á. M. M., Sánchez, E. M., Gomez-Peralta, F., Umpierrez, G. E., & Brocca, M. A. M. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261492377
Metadata
- Authors
- Seidu, S., Kunutsor, S. K., Ajjan, R. A., & Choudhary, P.
- Affiliations
- University of Leicester (GB)
- University of Leeds (GB)
- Corresponding author
- Seidu, Samuel
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-20
- Volume
- 47
- Issue
- 1
- Pages
- 169-179
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W4389988073
- Cited by
- 124
- References
- 29
- Citations by year
- 2026: 50 · 2025: 57 · 2024: 17
- FWCI
- 4.45
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- NIHR Leicester Biomedical Research Centre
- National Institute for Health Research
- Applied Research Collaboration East Midlands
- ARC
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- continuous glucose monitoring, intermittently scanned continuous glucose monitoring, type 2 diabetes, glycemic control, HbA1c, self-monitoring of blood glucose, user satisfaction, adverse events, body composition, blood pressure, serum lipids, diabetes self-management
- MeSH terms
- Continuous Glucose Monitoring, Adult, Blood Glucose, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Lipids, Blood Glucose Self-Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.